supported by the National Key Research and Development Program of China(2017YFA0205200);the National Natural Science Foundation of China(81571785,81771957,81901857,81801811);Natural Science Foundation of Guangdong Province,China(2018A030313074)to Dr.Ligong Lu;the Zhuhai Municipal Science and Technology Foundation(ZH22046301200004PWC)to Dr.Shi-You Li;the Sunny Li Family fund to You-Wen He。
The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019(C...
Supported by the National Natural Science Foundation of China,No.81174263;National Science and Technology Major Project during the 12th Five-year Plan Period,No.2012ZX1005006;Sanming Project of Medicine in Shenzhen,Guangdong Province,China,No.SZSM201612074;and Science and Technology Planning Project of Guangdong Province,China,No.2017A020213016.
BACKGROUND No guideline recommends antiviral therapy for hepatitis B e antigen(HBeAg)-positive chronic hepatitis B patients with persistently normal alanine aminotransferase levels and a high hepatitis B virus(HBV)DNA...
Supported by National Natural Science Foundation of China,Grant No.81241073;Peking University Cancer Hospital Foundation for Scientific Research,Grant No.2013-Autonomous-9
Reactivation of hepatitis B virus(HBV)can occur in lymphoma patients infected with HBV when they receive chemotherapy or immunotherapy.Prophylactic administration of lamivudine(LAM)reduces the morbidity and mortality ...
supported by Ningbo Natural Science Foundation (No. 2012A610183; No. 2013A610239)
Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBe Ag-positive chronic hepatitis B(CHB) and explore whether liver histopathological features and other factors might influe...
supported by the National Basic Research Program of China (Grant Nos. 2005CB522902 and 2007CB512900);the National High Technology Research and Development Program of China (Grant No. 2006AA02A410);the National Natural Science Foundation of China (Grant No. 30901256);the Beijing Natural Science Foundation (Grant No. 7102153);National Science and Technology Major Project for Infectious Diseases Control During the 11th Five-Year Plan Period (Grant Nos. 2008ZX10002-012 and 2008ZX10002-013);Peking University People’s Hospital Research Development Funds (Grant No. RDC 2009-13);Key Clinical Research Program of Ministry of Health of China
The efficacy of interferon (IFN) is limited in about 1/3 of patients with chronic hepatitis B (CHB). We used two-dimensional electrophoresis (2-DE)-based proteomic strategies to identify potential serum markers predic...